The FDA has called off Voyager gene therapy to treat Huntington's disease.

2020.10.14 RESEARCHNEWS Lilly COVID-19 antibody trial was also suspended; Hesco Class 1 innovative drug FTP-198 tablets were declared clinically accepted; AstraZenecon/First Triple Weight ADC Therapy submitted another clinical trial application in China... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
(click on the title, read the original) Lilly COVID-19 antibody trial was also suspended, the National Institutes of Health asked to suspend Lilly and AbCellera for COVID-19 hospitalized patients monoclonal antibody (LY-CoV555) treatment trial (ACTIV-3) recruitment of new patients.
the FDA called off the Voyager gene therapy to treat Huntington's disease, the FDA issued a clinical stay of the company's application for a new drug for VY-HTT01, a gene therapy used to treat Huntington's disease.
submitted an IND application for clinical studies of the drug program to the FDA in September.
fda said the shelving of the project was mainly due to waiting for some chemical, manufacturing and control issues to be resolved.
(Drug Approval) Haisco Class 1 innovative drug FTP-198 tablets declared clinical acceptance 14, Haisco issued a notice that the wholly-owned subsidiary Sichuan Haisco Pharmaceutical Co., Ltd. recently received the State Drug Administration issued a "notice of acceptance", in accordance with the provisions of Article 32 of the Administrative Licensing Law of the People's Republic of China, after review, decided to accept.
5 new drugs to be included in the priority review from Beda Pharmaceuticals, AstraZeneta, Bayer and other 12, CDE website announced that 5 new drug listing applications to be included in the priority review.
These products are Beda Pharmaceuticals Class 1 new drug Ektini, AstraZeneone EGFR-TKI Ochitini, Zeitogen Pharmaceuticals liver cancer new drug Donafini, Bayer anti-thrombosis product Devasaban, Sanofi "double target" antibody dupilumab.
Huali Pharmaceuticals obtained dozagliatin "drug production license" today, Huali Pharmaceutical announced that after the drug market license holder system audit and on-site verification, the company has been issued by the Shanghai Municipal Drug Administration in the study of the world's first innovative drug Dozagliatin "drug production license."
AstraZeneca/First Three-Weight ADC Therapy submitted another clinical trial application in China on the 14th, the CDE website recently announced that the first three in China submitted a new clinical trial application for the antibody concedes drug Enhertu (DS-8201).
HER2-targeted ADC therapy is a key development for AstraZeneta and Phase 3, with a $6.9 billion partnership behind it.
the first CD19 single anti-reported listing 14, CDE official website shows that Viela Bio submitted CD19 single anti-Inebilizumab injection new drug market application and was accepted.
as early as May 2019, Howson acquired an interest in the development and commercialization of the drug in China with a down payment of more than $220 million plus milestone payments.
Baotai's third product submitted for listing application on the 14th, Baaotai developed the first class 1 chemical drug Bati non-class injection submitted a listing application, this new drug from the first declaration of clinical in 2005 to today's declaration of listing, before and after more than 15 years of research and development.
.